PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Articles|March 2, 2019
- Pharmaceutical Technology-03-02-2019
- Volume 43
- Issue 3
Reactor Flask Heating System
The DrySyn UNO Base by Asynt offers a way to conduct safe experiments in academic teaching and research labs.
The DrySyn UNO Base by Asynt offers a way to conduct safe experiments in academic teaching and research labs. The versatile entry-level reactor flask heating system has a heat resistant handle that enables safe heating and clamping of a single flask or vial using a DrySyn Reaction Vial insert.
The base itself has a flat bottom with removable/repositionable feet that makes it suitable for use on any standard magnetic hotplate stirrer. The base is constructed of solid anodized aluminum, which enhances the heating system’s performance without the need for messy and potentially hazardous oil baths, according to the company.
Articles in this issue
over 7 years ago
Tablet Press Refurbishment: Why and How?over 7 years ago
Embracing the Digital Factory for Bio/Pharma Manufacturingover 7 years ago
Caught in a Conundrumover 7 years ago
Strategic Screening for Solubility Solutionsover 7 years ago
Monoplant: Advantages of a Dedicated Facilityover 7 years ago
Handle with Careover 7 years ago
Rising to the Challenge of Biologic Drug Formulationover 7 years ago
Can the Price Ever be Right?over 7 years ago
Europe Pushes for Global Easing of Generics Approvalsover 7 years ago
Key Considerations in Stability TestingRelated to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.